Valuation: CORESTEMCHEMON Inc.

Market Cap	100B 73.56M 65.33M 61.1M 55.68M 105M 7.08B 106M 739M 286M 3.61B 276M 270M 11.58B	P/E 2024	-3.45x	P/E 2025	-2.05x
Enterprise Value	131B 96.12M 85.38M 79.84M 72.76M 137M 9.25B 139M 966M 374M 4.71B 361M 353M 15.14B	EV / Sales 2024	4.76x	EV / Sales 2025	5.59x
Free-Float	81.23%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news: CORESTEMCHEMON Inc.

07-18	CORESTEMCHEMON Inc. Announces South Korea's MFDS Allows Neuronata-R to Remain on Market, Preserving Conditional Approval for Als Treatment	CI
12-18	Corestemchemon Advances Toward Als Stem Cell Commercialization with Regulatory Progress in Korea and Nsf-Backed U.S. Expansion	CI
25-09-21	CORESTEMCHEMON Inc.(KOSDAQ:A166480) dropped from S&P Global BMI Index	CI
25-09-18	Neuronata- Phase 3 Results Confirm Subgroup Benefit at PACTALS 2025, Strengthening Biomarker-Driven Pathway	CI
25-07-21	Corestemchemon to divest 2.7 billion won worth of own shares	RE
25-07-21	CorestemChemon Expands Global CRO Reach with ATG Lifetech, Targeting Next-Gen Preclinical Services	CI
25-05-29	Corestemchemon Announces Neuronata-R®? Stem Cell Therapy Shows Promise in Als Phase 3 Subgroup Analysis, Moves Toward Fda Accelerated Approval	CI
25-05-29	Neuronata-R® Stem Cell Therapy Shows Promise in ALS Phase 3 Subgroup Analysis	RE
25-05-07	Corestemchemon To Divest 3.4 Billion Won Worth Of Own Shares	RE
25-03-26	Corestemchemon To Divest 3.6 Billion Won Worth Of Own Shares	RE
24-09-22	CORESTEMCHEMON Inc.(KOSDAQ:A166480) added to S&P Global BMI Index	CI
24-03-25	CORESTEMCHEMON Inc. announced that it has received KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd.	CI
24-03-21	CORESTEMCHEMON Inc. announced that it expects to receive KRW 21 billion in funding from NH Investment & Securities Co., Ltd., Samsung Securities Co., Ltd. and another investor	CI

More news

Managers and Directors: CORESTEMCHEMON Inc.

Manager	Title	Age	Since
Gil-Ahn Yang CEO	Chief Executive Officer	70	-
Si-Hwan Song PSD	President	65	2000-07-31
Gwang-Soon Kwon PSD	President	54	-

Director	Title	Age	Since
Gyeong-Sook Kim BRD	Director/Board Member	61	2015-06-15
Gwang-Soon Kwon BRD	Director/Board Member	54	-
Gil-Ahn Yang BRD	Director/Board Member	70	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
CORESTEMCHEMON INC.	+2.26%	+6.35%	+30.79%	-64.24%	73.56M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.41B
ARGENX SE	-1.14%	-1.63%	+24.31%	+78.03%	59.26B
LONZA GROUP AG	+1.20%	-0.53%	+4.39%	+34.65%	47.14B
IQVIA HOLDINGS INC.	-3.02%	-5.20%	+27.94%	+32.51%	42.91B
REVOLUTION MEDICINES, INC.	+0.31%	+3.02%	+348.95%	+643.82%	44.13B
BEONE MEDICINES AG	-1.96%	-0.33%	+7.04%	+99.46%	40.79B
CELLTRION, INC.	+3.32%	+3.49%	+10.10%	+51.23%	30.77B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+22.72%	29.31B
INSMED INCORPORATED	-4.86%	-10.66%	-26.27%	+330.06%	23.71B
Average	-0.25%	+0.16%	+50.63%	+132.24%	39.25B
Weighted average by Cap.	+0.02%	-0.32%	+58.00%	+145.71%

See all sector performances

Corestemchemon Inc, formerly Corestem Inc, is a Korea-based company engaged in the development, production and sale of stem cell therapies for intractable diseases. The Company operates its business through two segments. The Non-clinical Contract Research Organization (CRO) Business segment is engaged in the provision of research and development services such as toxicity (safety) verification and drug efficacy (efficacy) verification in the non-clinical stage. The Cell Therapy Business segment is engaged in the development, production and sale of Lou Gehrig's disease treatments such as Neuronata-R.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-10-01	₩2,260.00	+2.26%	94,769
26-09-30	₩2,210.00	+1.38%	113,466
26-09-29	₩2,180.00	-0.68%	45,326
26-09-28	₩2,195.00	+3.29%	143,189
26-09-23	₩2,125.00	+2.66%	99,187

End-of-day quote Korea S.E.

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Korea S.E. 2026-10-01			5-day change	1st Jan Change
2,260.00 ^KRW	+2.26%		+6.35%	+22.29%

1 day	+2.26%
1 week	+6.35%
Current month	+2.26%
1 month	+2.73%
3 months	+2.73%
6 months	-10.67%
Current year	+22.29%

1 week	2,125	2,290
1 month	2,005	2,305
Current year	1,642	6,100
1 year	1,014	6,100
3 years	1,014	15,610
5 years	1,014	19,800
10 years	1,014	34,350

Date	Insider	Type	Main position	Quantity	% Market Cap.	Importance
5/2/25	Tae-Yong Lee	Sell	Chief Technology Officer	64,262	0.1955%
5/2/25	Gwang-Soon Kwon	Sell	Chairperson	151,072	0.4596%
10/7/24	Ryeong Lee	Others		1,875	0.0057%	-

	2024	2025
Net sales	28.76B 21.1M 18.74M 17.53M 15.97M 30.07M 2.03B 30.49M 212M 82.09M 1.03B 79.23M 77.51M 3.32B	20.16B 14.79M 13.14M 12.29M 11.2M 21.08M 1.42B 21.37M 149M 57.53M 725M 55.53M 54.33M 2.33B
Net income	-26.25B -19.26M -17.11M -16M -14.58M -27.45M -1.85B -27.82M -194M -74.92M -944M -72.32M -70.75M -3.03B	-26.83B -19.69M -17.49M -16.35M -14.9M -28.05M -1.9B -28.44M -198M -76.58M -965M -73.92M -72.31M -3.1B
Net Debt	42.32B 31.05M 27.58M 25.79M 23.51M 44.25M 2.99B 44.86M 312M 121M 1.52B 117M 114M 4.89B	30.76B 22.57M 20.04M 18.74M 17.08M 32.16M 2.17B 32.6M 227M 87.78M 1.11B 84.73M 82.89M 3.55B

CORESTEMCHEMON Inc. Stock

Stocks

A166480

KR7166480004

Biotechnology & Medical Research

Valuation: CORESTEMCHEMON Inc.

Chart: CORESTEMCHEMON Inc.

Latest news: CORESTEMCHEMON Inc.

Quotes and Performance

Price Extremes

Managers and Directors: CORESTEMCHEMON Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes